| Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and … SD Banister, M Longworth, R Kevin, S Sachdev, M Santiago, J Stuart, ... ACS Chemical Neuroscience 7 (9), 1241-1254, 2016 | 256 | 2016 |
| Pharmacology of indole and indazole synthetic cannabinoid designer drugs ab-fubinaca, adb-fubinaca, ab-pinaca, adb-pinaca, 5f-ab-pinaca, 5f-adb-pinaca, adbica, and 5f-adbica SD Banister, M Moir, J Stuart, RC Kevin, KE Wood, M Longworth, ... ACS chemical neuroscience 6 (9), 1546-1559, 2015 | 238 | 2015 |
| Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135 SD Banister, J Stuart, RC Kevin, A Edington, M Longworth, SM Wilkinson, ... ACS Chemical Neuroscience 6 (8), 1445-1458, 2015 | 218 | 2015 |
| Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition TR Arkell, N Lintzeris, RC Kevin, JG Ramaekers, R Vandrey, C Irwin, ... Psychopharmacology 236, 2713-2724, 2019 | 183 | 2019 |
| Acute prosocial effects of oxytocin and vasopressin when given alone or in combination with 3, 4-methylenedioxymethamphetamine in rats: involvement of the V1A receptor L Ramos, C Hicks, R Kevin, A Caminer, R Narlawar, M Kassiou, ... Neuropsychopharmacology 38 (11), 2249, 2013 | 141 | 2013 |
| Effect of cannabidiol and Δ9-tetrahydrocannabinol on driving performance: a randomized clinical trial TR Arkell, F Vinckenbosch, RC Kevin, EL Theunissen, IS McGregor, ... Jama 324 (21), 2177-2186, 2020 | 135 | 2020 |
| Nabiximols for the treatment of cannabis dependence: A randomized clinical trial N Lintzeris, A Bhardwaj, L Mills, A Dunlop, J Copeland, I McGregor, ... JAMA Internal Medicine, 2019 | 91 | 2019 |
| Synthesis and in Vitro Cannabinoid Receptor 1 Activity of Recently Detected Synthetic Cannabinoids 4F-MDMB-BICA, 5F-MPP-PICA, MMB-4en-PICA, CUMYL … A Cannaert, E Sparkes, E Pike, JL Luo, A Fang, RC Kevin, R Ellison, ... ACS Chemical Neuroscience 11 (24), 4434-4446, 2020 | 89 | 2020 |
| Molecular and behavioral pharmacological characterization of abused synthetic cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-fluoro-CUMYL-PICA TF Gamage, CE Farquhar, TW Lefever, JA Marusich, RC Kevin, ... The Journal of Pharmacology and Experimental Therapeutics, 2018 | 79 | 2018 |
| Composition and use of cannabis extracts for childhood epilepsy in the Australian community A Suraev, N Lintzeris, J Stuart, RC Kevin, R Blackburn, E Richards, ... Scientific reports 8 (1), 10154, 2018 | 72 | 2018 |
| Pharmacology of cumyl-carboxamide synthetic cannabinoid new psychoactive substances (NPS) CUMYL-BICA, CUMYL-PICA, CUMYL-5F-PICA, CUMYL-5F-PINACA, and their analogues M Longworth, SD Banister, R Boyd, RC Kevin, M Connor, IS McGregor, ... ACS Chemical Neuroscience 8 (10), 2159-2167, 2017 | 62 | 2017 |
| Defensive aggregation (huddling) in Rattus norvegicus toward predator odor: individual differences, social buffering effects and neural correlates MT Bowen, RC Kevin, M May, LG Staples, GE Hunt, IS McGregor PLoS One 8 (7), e68483, 2013 | 60 | 2013 |
| Synthesis and pharmacology of new psychoactive substance 5F‐CUMYL‐P7AICA, a scaffold‐hopping analog of synthetic cannabinoid receptor agonists 5F‐CUMYL‐PICA and 5F‐CUMYL‐PINACA SD Banister, A Adams, RC Kevin, C Macdonald, M Glass, R Boyd, ... Drug testing and analysis 11 (2), 279-291, 2019 | 52 | 2019 |
| In vitro and in vivo pharmacokinetics and metabolism of synthetic cannabinoids CUMYL-PICA and 5F-CUMYL-PICA RC Kevin, TW Lefever, RW Snyder, PR Patel, TR Fennel, JL Wiley, ... Forensic Toxicology, 2017 | 52 | 2017 |
| Cannabidiol for treatment-resistant anxiety disorders in young people: an open-label trial M Berger, E Li, S Rice, CG Davey, A Ratheesh, S Adams, H Jackson, ... The Journal of clinical psychiatry 83 (5), 42111, 2022 | 51 | 2022 |
| The failings of per se limits to detect cannabis-induced driving impairment: Results from a simulated driving study TR Arkell, TR Spindle, RC Kevin, R Vandrey, IS McGregor Traffic injury prevention 22 (2), 102-107, 2021 | 48 | 2021 |
| Synthetic cannabinoid hydroxypentyl metabolites retain efficacy at human cannabinoid receptors TF Gamage, CE Farquhar, RJ McKinnie, RC Kevin, IS McGregor, ... Journal of Pharmacology and Experimental Therapeutics 368 (3), 414-422, 2019 | 47 | 2019 |
| Detection of Δ9 THC in oral fluid following vaporized cannabis with varied cannabidiol (CBD) content: An evaluation of two point‐of‐collection testing devices TR Arkell, RC Kevin, J Stuart, N Lintzeris, PS Haber, JG Ramaekers, ... Drug testing and analysis 11 (10), 1486-1497, 2019 | 46 | 2019 |
| Vaping Synthetic Cannabinoids: A Novel Preclinical Model of E-Cigarette Use in Mice TW Lefever, JA Marusich, BF Thomas, DG Barrus, NC Peiper, RC Kevin, ... Substance Abuse: Research and Treatment, 2017 | 46 | 2017 |
| Thermolytic degradation of synthetic cannabinoids: chemical exposures and pharmacological consequences BF Thomas, TW Lefever, RA Cortes, AL Kovach, AO Cox, PR Patel, ... J Pharmacol Exp Ther, 2017 | 45 | 2017 |
Iain S. McGregorUniversity of SydneyVerified email at sydney.edu.au
